GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EXMceuticals Inc (FRA:9OM1) » Definitions » Net Income

EXMceuticals (FRA:9OM1) Net Income : €-6.29 Mil (TTM As of Mar. 2021)


View and export this data going back to 2015. Start your Free Trial

What is EXMceuticals Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. EXMceuticals's Net Income for the three months ended in Mar. 2021 was €-1.63 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2021 was €-6.29 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. EXMceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2021 was €-0.02.


EXMceuticals Net Income Historical Data

The historical data trend for EXMceuticals's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EXMceuticals Net Income Chart

EXMceuticals Annual Data
Trend Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.34 -0.10 -0.22 -6.45 -6.06

EXMceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.85 -2.14 -1.43 -1.09 -1.63

EXMceuticals Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

EXMceuticals's Net Income for the fiscal year that ended in Jun. 2020 is calculated as

Net Income(A: Jun. 2020 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-6.505+0+0+0.442
=-6.06

EXMceuticals's Net Income for the quarter that ended in Mar. 2021 is calculated as

Net Income(Q: Mar. 2021 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.626+0+0+0
=-1.63

Net Income for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EXMceuticals  (FRA:9OM1) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

EXMceuticals's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2021 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


EXMceuticals Net Income Related Terms

Thank you for viewing the detailed overview of EXMceuticals's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


EXMceuticals (FRA:9OM1) Business Description

Traded in Other Exchanges
N/A
Address
421 7th Avenue S.W., 30th Floor, Calgary, AB, CAN, T2P 4K9
EXMceuticals Inc is a bio-science company that believes in the potential health and wellness benefits of hemp and cannabis. EXM is an emerging player in the market, with ambition and potential to become the suppliers of highest-grade cannabis ingredients. It is creating an industrial-scale, GMP, Pharmaceutical Grade Extraction and Refining facility inside the European Union, near Lisbon Portugal. It has an existing and licensed cannabis R&D facility and pilot refinery in Lisbon Portugal. EXM is targeting the B2B marketplace and will supply pure ingredients and API's to the pharmaceutical, medicinal and wellness industry.

EXMceuticals (FRA:9OM1) Headlines

No Headlines